Skip to main content

Table 4 Patients receiving prothombin complex concentrate dose in compliance with recommendations of the French National Health Authority (Haute Autorité de Santé)

From: Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice

Initial international normalized ratio 2-2.5
(n= 57)
2.5-3
(n= 53)
3-3.5
(n= 49)
> 3.5
(n= 249)
Unknown
(n= 71)
Patients with infused dose < expected dose 1 (1.8) 6 (11.3) 15 (30.6) 182 (73.1) 24 (34.7)
Patients with infused dose = expected dose 9 (15.8) 22 (41.5) 20 (40.8) 67 (26.9) 47 (65.3)
Patients with infused dose > expected dose 47 (82.5) 25 (47.2) 14 (28.6) 0 0
  1. Results are expressed as number (percentage). Results are presented in patients with documented prothombin complex concentrate dose and initial international normalized ratio (INR) of at least 2 or unknown INR (n = 479).